AIDSinfo invites you to view our patient fact sheets on three medications recently approved by the FDA. The three medications are all indicated for use in the treatment of HIV infection in adults. The patient fact sheets include information on dosage forms and strengths, possible side effects, and instructions on how to take and store the medications.
  • Fact sheet on cobicistat (brand name: Tybost)

    Cobicistat is a pharmacokinetic enhancer indicated for use with atazanavir (brand name: Reyataz) or darunavir (brand name: Prezista) to increase the amount of those medicines in the blood; it must be used in combination with other HIV medicines as well. 
  • Fact sheet on elvitegravir (brand name: Vitekta)

    Elvitegravir is an integrase inhibitor approved to treat HIV infection in adults who are already taking or have previously taken HIV medicines. Elvitegravir must be used in combination with an HIV protease inhibitor coadministered with ritonavir (brand name: Norvir) and another HIV medicine.
Visit the Drugs section of the AIDSinfo website to view the fact sheets and FDA labels for the three medications.
"New research has illuminated the movement and complete structure of the spikes on HIV that the virus uses to bind to the cells it infects. This research, led by scientists at the National Institutes of Health, Weill Cornell Medical College and Yale University School of Medicine, could help advance efforts to develop HIV vaccines and treatments."

For more information, view the NIAID press release.
"An NIAID study suggests that the increased frequency of an immune cell called CD14++CD16- monocyte is a strong indicator that a patient with HIV and tuberculosis (TB) may develop complications from anti-HIV drugs. For unclear reasons, a subset of people with both HIV and TB experience worsening of their TB symptoms after starting antiretroviral therapy (ART) to treat HIV. The study, which appears in the October 2, 2014, issue of PLOS Pathogens, offers a better understanding of why this may occur."

Visit the NIAID website to read the complete article.
National Latino AIDS Awareness Day is observed annually to highlight the disproportionate burden of HIV among Hispanics/Latinos. According to the Centers for Disease Control and Prevention (CDC), Hispanics/Latinos—despite representing only 16% of the U.S. population—accounted for 21% of new HIV infections in 2010.

Explore our National Latino AIDS Awareness Day webpage [en español] to learn more about the annual observance and to find information about HIV in the Hispanic/Latino population.
"On September 24, 2014, FDA approved Tybost (cobicistat) 150 mg tablets. Tybost is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection."

For more information on cobicistat, view the FDA press release.

"On September 24, 2014, FDA approved Vitekta (elvitegravir) 85 mg and 150 mg tablets. Vitekta is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor indicated in combination with an HIV protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) for the treatment of HIV-1 infection in antiretroviral treatment-experienced adults."

For more information on elvitegravir, view the FDA press release.

The labeling for both drugs will be available soon at the FDA website
The Centers for Disease Control and Prevention (CDC) is seeking public comments on a newly developed draft clinical quality measure for HIV infection screening. The measure aligns with the U.S. Preventive Services Task Force (USPSTF) recommendations that all individuals between the ages of 15 and 65 be screened for HIV. The measure was developed in collaboration with clinicians and quality experts. The goal is to develop a measure that will be nationally endorsed through the National Quality Forum (NQF) and included in the Centers for Medicare and Medicaid Services (CMS) programs.

Public comments will be accepted through October 20, 2014. For information on how to submit comments, please view the public notice on the CMS website.
CDC recently launched HIV Treatment Works, a new national campaign focused on encouraging people infected with HIV to get into care and adhere to treatment. The website includes information and resources for people living with HIV, including information on treatment adherence and tips for healthy living. Visit the HIV Treatment Works website to find an HIV care provider, an HIV support group, or mental health provider.

For more information, view the CDC press release
September 27 is the annual observance of National Gay Men’s HIV/AIDS Awareness Day, which serves to highlight the continuing impact of the HIV/AIDS epidemic among gay men. Gay and bisexual men are more severely affected by HIV than any other group in the United States. According to CDC, gay, bisexual, and other men who have sex with men (MSM) represent approximately 2% of the U.S. population but accounted for 63% of estimated new HIV infections in 2010.

Explore our National Gay Men’s HIV/AIDS Awareness Day webpage [en español] to learn more about this observance and to find information on HIV/AIDS and gay men.
On August 28, 2014, FDA approved updates to the label for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300 mg) fixed-dose combination tablets. The label was updated with efficacy, resistance, and safety data from two clinical trials; renal information; and drug interaction information.

The updated labeling for Stribild is available at the FDA website

More information is available: 
National HIV/AIDS and Aging Awareness Day is a day set aside each year to recognize the impact of HIV/AIDS among older adults. According to the Centers for Disease Control and Prevention (CDC), adults aged 55 and older accounted for 19% of the estimated 1.1 million people living with HIV infection in the United States in 2010. Older Americans are more likely than younger Americans to be diagnosed with HIV infection late in the course of their disease, which may mean a later start to treatment, possibly causing more damage to their immune system. This can lead to poorer prognoses and shorter HIV-to-AIDS intervals.

Visit our National HIV/AIDS and Aging Awareness Day webpage [en español] to learn more about this observance and to find information on HIV/AIDS and aging.


  • Categories:

    • Locations: